American Oncology Network, Inc.: Nasdaq/NYSE listing notice — DTOC receives Nasdaq notice for failure to meet minimum public float requirement

American Oncology Network, Inc.

Nasdaq letter on April 20, 2023 states DTOC does not meet minimum 500,000 publicly held shares (Public Float Standard).
Company has until June 5, 2023 to submit a plan to achieve compliance; no immediate effect on listing or trading.
DTOC intends to submit plan and references business combination agreement with American Oncology Network (announced Oct 5, 2022) to regain compliance.
If Nasdaq rejects plan, DTOC may appeal to a Nasdaq Hearings Panel.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

American Oncology Network, Inc. received a nasdaq noncompliance notice notice regarding other (rules 5550(a)(4)).

Exchange: nasdaq
Notice: noncompliance notice
Rules: 5550(a)(4)

Exact text from the filing

April 20, 2023, Digital Transformation Opportunities Corp. (the “Company”) received a letter (the “Public Float Notice”) from the listing qualifications department staff of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that the Company no longer meets the minimum 500,000 publicly held shares required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(4) (the “Public Float Standard”). The Public Float Notice states that the Company has until June 5, 2023 to provide Nasdaq with a specific plan to achieve and sustain compliance with all The N

View on SEC.gov

Browse all listing & compliance notices →

Source: SEC EDGAR

accession 0001104659-23-049209

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.